Trade Mark Journal No.2025/046 14 November 2025
WO0000001875401 (1,40,42)
Office of origin: United States of America
Date of International Registration:28 March 2025
Date of designation in the UK:
28 March 2025
International priority date claimed: 1 October 2024
(United States of America)
(98780101)
- Class 1
- Biochemical preparations for scientific purposes; biochemical reagents used for non-medical purposes; biological tissue, namely, cells for use in scientific, medical research, manufacturing of viral vectors and commercial applications in relation to cell and gene therapies for use in scientific and medical research; cells for scientific and research use; cells for scientific, laboratory or medical research; reagents for scientific or medical research use.
- Class 40
- Custom manufacture of cells and vectors for diagnostic, medical, research, clinical and commercial applications in relation to cell and gene therapies by pharmaceutical compounders; manufacturing services for others in the field of biotechnology.
- Class 42
- Biological research laboratory services; gene therapy research; research and development services in the field of gene expression systems; research and development services relating to vaccines; scientific and technological services, namely, laboratory services for biomanufacturing of viral vectors in the field of cell and gene therapy; scientific research in the field of cell and gene therapy; testing, inspection, research, or development of pharmaceutical preparations for gene therapy; biological engineering; cell line engineering; bioproduction cell line engineering.
Revvity Gene Delivery GmbH
Representative: Cleveland Scott York, 5 Norwich Street London EC4A 1DR UNITED KINGDOM